Amgen registers Phase 3 study of inebilizumab in primary membranous nephropathy
This study was first posted on ClinicalTrials.gov on October 1, 2026. The study plans to enroll 159 participants and aims to evaluate the efficacy of inebilizumab on PMN disease activity as measured by complete remission.
Primary source
ClinicalTrials.gov registry record, October 1, 2026
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
Read the source: A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation